Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated poliovirus vaccine + fractional inactivated poliovirus vaccine + Rotarix
- Development stage
- Unknown
- Lead developer
- Centers for Disease Control and Prevention
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intradermal, Oral
01
Overview
This combination refers to a vaccination regimen evaluated in a Phase IV clinical trial (NCT03332732) led by the Centers for Disease Control and Prevention (CDC). The regimen consists of the standard Inactivated Poliovirus Vaccine (IPV), a fractional dose of the Inactivated Poliovirus Vaccine (fIPV) delivered intradermally as a booster, and the Rotarix rotavirus vaccine. IPV and fIPV provide active immunity against poliomyelitis by inducing neutralizing antibodies to poliovirus types 1, 2, and 3. Rotarix is a live-attenuated monovalent human rotavirus vaccine (strain RIX4414) designed to prevent gastroenteritis caused by rotavirus. The study specifically investigates the immunogenicity and optimization of polio vaccination schedules, including dose-sparing fractional doses, when administered concomitantly with rotavirus vaccines in infants.
- Other names
- IPVfIPVRotavirus vaccine
02
Targets
CD4+ T-cell receptor recognizing poliovirus capsid-derived peptidesPV-TCR (Poliovirus capsid-specific CD8+ T-cell receptor)PRR (Pattern recognition receptors)PV-D-BCR (Naïve B-cell receptor specific for poliovirus D-antigen)B-cell receptor specific for rotavirus VP7 and VP4VP4 (Rotavirus VP4)VP7 (Rotavirus VP7 outer capsid glycoprotein)
Beyond the preview
Go deeper on inactivated poliovirus vaccine + fractional inactivated poliovirus vaccine + Rotarix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated poliovirus vaccine + fractional inactivated poliovirus vaccine + Rotarix.